Has Damian Silbermins, MD received payments from drug or device companies?

Yes. Drug and device makers reported $292,836 in general payments to Damian Silbermins, MD across 1,247 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Damian Silbermins, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Damian Silbermins, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Damian Silbermins, MD

Hematology & Oncology · Huntington, WVNPI 1922207117

Payments from drug & device makers

$292,836in general payments, 2019–2025

Across 1,247 payments — averaging $234.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$180K
Bristol Myers Squibb$27K
AstraZeneca$13K
Jazz Pharmaceuticals Inc.$10K
Amgen$9K
Novartis$8K
plus $45K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	221	$179,798
Bristol Myers Squibb	62	$27,350
AstraZeneca(2 entities)	51	$13,203
Jazz Pharmaceuticals Inc.	21	$9,758
Amgen	25	$9,402
Novartis	134	$7,990
Johnson & Johnson(2 entities)	102	$7,748
Hoffmann-la Roche Limited	1	$7,038
Incyte Corporation	33	$6,467
Agios Pharmaceuticals, Inc.	15	$4,361
Seagen Inc.	35	$2,718
Beone Medicines USA, Inc.	6	$2,058
Daiichi Sankyo Inc.	43	$1,990
Rigel Pharmaceuticals, Inc.	12	$1,366
Bayer	10	$1,059
Pfizer	52	$822
Merck	43	$804
Genentech USA, Inc.	41	$776
Astellas Pharma US Inc	30	$713
Beigene, Ltd.	1	$525
Exelixis Inc.	6	$502
Ipsen Biopharmaceuticals, Inc	21	$467
AbbVie	24	$467
Beigene USA, Inc.	9	$380
Pharmacyclics LLC, An Abbvie Company	18	$352
GSK	18	$334
Sanofi	13	$265
Takeda Pharmaceuticals U.S.A., Inc.	8	$208
EMD Serono, Inc.	10	$189
Eisai Inc.	9	$175
Tempus AI, Inc	12	$173
Gilead(2 entities)	12	$171
Coherus Oncology, Inc.	8	$165
Taiho Oncology, Inc.	6	$155
Tersera Therapeutics LLC	6	$152
Shield Therapeutics Inc	3	$148
G1 Therapeutics, Inc.	2	$148
Histosonics, Inc.	1	$142
Lilly USA, LLC	9	$138
Novocure Inc.	8	$134
Morphosys, US Inc.	6	$133
Array Biopharma Inc	8	$132
ADC Therapeutics America, Inc.	8	$131
Puma Biotechnology, Inc.	8	$122
Blueprint Medicines Corporation	6	$113
Alnylam Pharmaceuticals Inc.	5	$103
AVEO Pharmaceuticals, Inc.	6	$100
Comsort, Inc	1	$100
Karyopharm Therapeutics Inc.	5	$91
Kyowa Kirin, Inc.	5	$86
Boehringer Ingelheim	5	$80
Foundation Medicine, Inc.	3	$70
Geron Corporation	2	$60
Mirati Therapeutics, Inc.	3	$59
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$50
Pharmacosmos Therapeutics Inc.	2	$45
Adaptive Biotechnologies Corporation	2	$43
Dova Pharmaceuticals	3	$42
AMAG Pharmaceuticals, Inc.	2	$40
Stemline Therapeutics Inc.	2	$36

How this compares

$292,836 in reported general payments places this provider in the 85th percentile of 72 hematology & oncology providers in West Virginia.

See all hematology & oncology providers in West Virginia →

Medicare billing

Part B allowed, 2024

$188,620

Medicare patients

499

Services billed

2,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Huntington

Arvinder BirHuntington$140K
Matias ValsecchiHuntington$17K
Maria TironaHuntington$13K
Toni PaciolesHuntington$11K
Mina ShenoudaHuntington$3K
Chathula KumarasingheHuntington$3K
Muhammad JamilHuntington$438
Ashkan EmadiMorgantown$8.7M
Lauren VeltriMorgantown$1.4M
Michael CraigMorgantown$1.4M

See the full list for West Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →